Aimmune Therapeutics Inc. (NASDAQ:AIMT) rose 1.8% on Monday . The company traded as high as $14.80 and last traded at $14.66, with a volume of 114,894 shares trading hands. The stock had previously closed at $14.40.

AIMT has been the subject of a number of research reports. Wedbush reiterated an “outperform” rating and set a $42.00 target price on shares of Aimmune Therapeutics in a research note on Monday, May 16th. Zacks Investment Research lowered shares of Aimmune Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, July 19th. Credit Suisse Group AG reiterated a “buy” rating and set a $35.00 target price on shares of Aimmune Therapeutics in a research note on Friday, August 19th. Piper Jaffray Cos. reiterated an “overweight” rating and set a $38.00 target price on shares of Aimmune Therapeutics in a research note on Tuesday, June 14th. Finally, Bank of America Corp. reiterated a “buy” rating on shares of Aimmune Therapeutics in a research note on Monday, May 16th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $33.40.

The stock’s 50 day moving average price is $12.10 and its 200 day moving average price is $13.77. The firm’s market capitalization is $665.29 million.

Aimmune Therapeutics (NASDAQ:AIMT) last announced its earnings results on Wednesday, August 10th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by $0.01. On average, analysts forecast that Aimmune Therapeutics Inc. will post ($1.71) earnings per share for the current year.

In other news, major shareholder Foresite Capital Fund Ii, L.P. sold 240,000 shares of Aimmune Therapeutics stock in a transaction dated Tuesday, May 31st. The shares were sold at an average price of $15.23, for a total value of $3,655,200.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

A hedge fund recently raised its stake in Aimmune Therapeutics stock. RS Investment Management Co. LLC raised its position in Aimmune Therapeutics Inc. (NASDAQ:AIMT) by 12.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 804,143 shares of the company’s stock after buying an additional 88,180 shares during the period. RS Investment Management Co. LLC owned about 1.90% of Aimmune Therapeutics worth $14,836,000 as of its most recent SEC filing.

Aimmune Therapeutics Inc, formerly Allergen Research Corporation, is a United States-based clinical-stage biopharmaceutical company. The Company focuses on therapeutic approach, including the development of proprietary candidates, for the treatment of peanut and other food allergies. The Company’s Characterized Oral Desensitization Immunotherapy (CODIT) is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.